GlassScriptPhysician profile
Zoe E Starceski
NPI 1982188033
$7,583.75
in general payments reported to CMS, 2019-2025
20 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $972 · 2022: $418 · 2023: $2,099 · 2024: $2,392 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,081 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,081.40 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,042.97 | 2022-2025 | |
| Axsome Therapeutics, INC. | $1,254.55 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $529.17 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $502.52 | 2022-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $490.17 | 2021 | |
| Alkermes, INC. | $414.33 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $262.46 | 2023-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $169.72 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.71 | 2023-2025 | Caplyta |
| Orexo US, INC. | $148.60 | 2021-2024 | Zubsolv |
| Corium, LLC | $140.44 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $133.60 | 2024-2025 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $97.63 | 2021 | |
| Lundbeck LLC | $63.63 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $39.72 | 2022-2025 | Invega Sustenna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36.27 | 2021 | |
| Pear Therapeutics (US), INC. | $33.59 | 2021 | |
| Supernus Pharmaceuticals, INC. | $32.64 | 2021-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $17.78 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $15.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoe Starceski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.